Clinical Trial: An Effectiveness & Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Colonoscopy

This study is not yet open for patient recruitment.
Verified by MGI Pharma November 2005

Sponsored by: MGI Pharma
Information provided by: MGI Pharma
ClinicalTrials.gov Identifier: NCT00261599

Purpose

Very often patients receive medication before a diagnostic procedure, like a colonoscopy, to help them relax and stay calm during the procedure This is called procedural or mild-to-moderate sedation. One product used for sedation is called propofol. AQUAVAN (fospropofol disodium) is made as a water soluble form of propofol allowing for rapid sedation and sedation during the entire procedure. This study is designed to test AQUAVAN for sedation during colonoscopy procedures.
Condition Intervention Phase
Colonoscopy
Colon Polyps
Endoscopic Outcomes
Endoscopic Sedation
Endoscopy
Conscious Sedation
 Drug: AQUAVAN® (fospropofol disodium) Injection
 Drug: Midazolam HCI
Phase III

MedlinePlus related topics:  Colonic Polyps

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title: A Phase 3, Randomized, Double-Blind, Dose-Controlled Study to Assess the Efficacy and Safety of AQUAVAN® (Fospropofol Disodium) Injection for Minimal to Moderate Sedation in Patients Undergoing Colonoscopy

Further study details as provided by MGI Pharma:
Primary Outcomes: Sedation Success - 3 consecutive Modified OAA/S scores of ≤4 after administration of sedative medication AND completing the procedure without requiring the use of alternative sedative medication AND without requiring manual or mechanical ventilation
Expected Total Enrollment:  300

Study start: December 2005;  Expected completion: April 2006
Last follow-up: March 2006;  Data entry closure: April 2006

This is a phase 3, randomized, double-blind, dose-controlled study designed to evaluate the efficacy and safety of a moderate dose of AQUAVAN compared to a minimally effective dose of AQUAVAN,,both following pretreatment with an analgesic fentanyl, in patients who are undergoing elective colonoscopy. A group of patients will receive midazolam as a reference therapy.

Following completion of preprocedure assessments, patients will be randomly assigned to 1 of 3 treatment groups at a 2:3:1 (AQUAVAN initial dose 1 [minimally effective dose]:AQUAVAN initial dose 2 [moderate dose]: initial Midazolam Reference Dose) allocation ratio on the day of the scheduled procedure.

A person skilled in airway management and authorized by the facility in which the colonoscopy is performed (such as a respiratory therapist, a study nurse, or a clinician) must be immediately available during the conduct of the study. All patients will be placed on supplemental oxygen via nasal cannula (4 L/min), and an ECG monitor, pulse oximeter, and blood pressure monitor will be attached prior to administration of study medication. All patients will receive an injection of analgesic pretreatment followed by the administration of study medication. This protocol recognized 2 distinct phases of sedation: Sedation Initiation and Sedation Maintenance. Assessments will be made to evaluate the patients for levels of sedation, clinical benefit of sedation, and adverse events. Blood samples will be collected for PK analysis.

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both
Criteria

Number of patients/site: Approximately 300 patients at up to 50 sites will be randomized into this study.

Study Country Location: United States

Inclusion Criteria:

  • Patient provides signed/dated Informed Consent and Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization after receiving a full explanation of the extent and nature of the study.
  • Patient must be at least 18 years of age at the time of screening.
  • If female, patient must be surgically sterile, postmenopausal, or not pregnant or lactating and must have been using an acceptable method of birth control for at least 1 month prior to dosing, with a negative urine pregnancy test result at screening and predose.
  • Patient meets American Society of Anesthesiologists (ASA) Physical Classification System status of P1 to P4.

Exclusion Criteria:

  • Patient has a history of allergic reaction or hypersensitivity to any anesthetic agent, opioid, or benzodiazepine.
  • Patient does not meet nils per os (NPO) status per ASA guidelines or institution’s guideline.
  • Patient has a Mallampati Classification Score of 4; OR a Mallampati Classification Score of 3 AND a thyromental distance ≤4 cm, or for any other reason has a difficult airway, in the opinion of the Investigator.
  • Patient has an abnormal, clinically significant 12-lead ECG finding at predosing period Day 0.
  • Patient has participated in an investigational drug study within 1 month prior to study start.
  • Patient is unwilling to adhere to pre- and postprocedural instructions.
  • Patient for whom the use of fentanyl citrate injection (fentanyl) is contraindicated.
  • Patient for whom the use of midazolam HCl injection (midazolam) is contraindicated.

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00261599


Maryland
      Endoscopic Microsurgery Associates, PA, Towson,  Maryland,  21204,  United States
Dale Tannenbaum  410-494-1946  Ext. 133    dalet@gastro-doc.com 

New York
      Research Associates of New York (New York Gastroenterology Associates), New York,  New York,  10021,  United States
Colleen D''''Souza  212-996-1105    rany@nyga.md 

Study chairs or principal investigators

James Jones, MD, PharmD,  Study Director,  MGI Pharma   

More Information

Study ID Numbers:  MGI 3000-0522
Last Updated:  December 8, 2005
Record first received:  December 1, 2005
ClinicalTrials.gov Identifier:  NCT00261599
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2006-01-10

Resources




Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us